Results 121 to 130 of about 6,532 (197)

Beyond CFTR: Ivacaftor's role in restoring cellular redox balance and preventing ferroptosis. [PDF]

Redox Biol
Rubin M, Artusi I, Rossetto M, Gucciardi A, Di Paolo ML, Bosello Travain V, Zeppilli D, Orian L, Miotto G, Friedmann Angeli JP, Cozza G.   +10 more
europepmc   +1 more source

Exposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes. [PDF]

Int J Neonatal Screen
Domenach L, Pagin A, Cisterne C, Audrezet MP, Couderc L, Monteil L, Roditis L, Murris M, Macey J, Fayon M, Bui S, Reboul MP.   +11 more
europepmc   +1 more source

Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]

Int J Mol Sci
Sankararaman S, Liu R, Sun X, Retuerto M, Schindler T, Roesch E, Sferra TJ, Drumm M, Ghannoum M, Zhang L.   +9 more
europepmc   +1 more source

Sinonasal and Pulmonary Computed Tomography Images Before and After Triple-Combination Therapy in a Patient with Cystic Fibrosis Without ΔF508 Mutations. [PDF]

Diagnostics (Basel)
Tagliati C, Campagna G, Di Sabatino M, Lanni G, Battista D, Ripani P.   +5 more
europepmc   +1 more source

Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by β-adrenergic plus cholinergic agonists. [PDF]

J Clin Invest
Joo NS, Birket SE, Keith JD, Ianowski JP, Luan X, Spano J, Bollyky JB, Dobry MN, Sabater JR, Williams RW, Engelhardt JF, Wine JJ, Milla CE.   +12 more
europepmc   +1 more source

Functional, Cohort-Level Assessment of CFTR Modulator Responses Using Biobanked Nasal Epithelial Cells from Individuals with Cystic Fibrosis. [PDF]

J Pers Med
Aalbers BL, Amatngalim GD, Aarts EM, Rodenburg LW, den Hertog-Oosterhoff LA, Heijerman HGM, Beekman JM.   +6 more
europepmc   +1 more source

The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I <i>CFTR</i> variants. [PDF]

Eur Respir J
Drai C, van der Woude HJ, Lexmond AJ, van den Hoorn T, Mol PGM, Leacy FP, Przybyszewska A, Sepodes B, Castelnovo T.   +8 more
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group .   +15 more
europepmc   +1 more source

Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis. [PDF]

EClinicalMedicine
Safeer V S M, Behl S, Vaidya PC, Tiwari P, Bharti SK, Nahan N, Kumar Sahu J, Bansal D.   +7 more
europepmc   +1 more source

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis. [PDF]

Cells
Lo Cicero S, Castelli G, Ceci A, Cerio AM, Blaconà G, Virgulti M, Allushi S, Sette G, Spadaro F, Amato F, Melotti P, Sorio C, Cimino G, Biffoni M, Lucarelli M, Eramo A.   +15 more
europepmc   +1 more source